Savara Inc SVRA:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 08/12/22 EDT
1.70quote price arrow down-0.01 (-0.58%)
Volume
2,146
Close
1.71quote price arrow up+0.01 (+0.59%)
Volume
89,297
52 week range
1.02 - 1.91
Loading...
  • Open1.69
  • Day High1.73
  • Day Low1.69
  • Prev Close1.70
  • 52 Week High1.91
  • 52 Week High Date07/11/22
  • 52 Week Low1.02
  • 52 Week Low Date03/14/22

Key Stats

  • Market Cap195.01M
  • Shares Out114.04M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.89
  • YTD % Change37.9

KEY STATS

  • Open1.69
  • Day High1.73
  • Day Low1.69
  • Prev Close1.70
  • 52 Week High1.91
  • 52 Week High Date07/11/22
  • 52 Week Low1.02
  • 52 Week Low Date03/14/22
  • Market Cap195.01M
  • Shares Out114.04M
  • 10 Day Average Volume0.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.89
  • YTD % Change37.9

RATIOS/PROFITABILITY

  • EPS (TTM)-0.28
  • P/E (TTM)-6.11
  • Fwd P/E (NTM)-6.26
  • EBITDA (TTM)-19.012M
  • ROE (TTM)-26.38%
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-4,544,500.00%
  • Debt To Equity (MRQ)18.91%

EVENTS

  • Earnings Date11/10/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Savara Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Savara Inc. is a clinical stage company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung...
Matthew Pauls J.D.
Chairman of the Board, Chief Executive Officer
David Lowrance CPA
Chief Financial Officer, Secretary
Address
6836 BEE CAVE ROAD
BUILDING 3, SUITE 201
Austin, TX
78746
United States

Top Peers

SYMBOLLASTCHG%CHG
RAIN
Rain Therapeutics Inc
8.01+0.33+4.30%
ANNX
Annexon Inc
6.12+0.50+8.90%
MTNB
Matinas BioPharma Holdings Inc
0.843-0.0037-0.437%
STSA
Satsuma Pharmaceuticals Inc
6.00+0.21+3.54%
SPPI
Spectrum Pharmaceuticals Inc
1.36+0.15+12.40%